-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Cerebral cavernous malformations (CCMs) can manifest as seizures, intracranial hemorrhage, focal neurological deficits, or incidentally on brain magnetic resonance imaging
Seizures, intracranial hemorrhage, and focal neurological deficits can also be detected incidentally on MRI of the brain
A study published in Stroke, an authoritative journal in the field of cardiovascular disease, aims to determine the relationship between beta-blocker or statin use and future symptomatic intracranial hemorrhage or intracranial cavernous malformation (CCM).
The population-based Scottish cohort of adults with intracranial vascular malformations prospectively identified adult residents of Scotland with a first diagnosis of CCM between 1999-2003 or 2006-2010
63 (21%) of 300 adults used beta-blockers (27/63 [43%] propranolol) and 73 (24%) used 3634 visits/years of follow-up statins
CONCLUSIONS: The use of beta-blockers, rather than statins, reduces the risk of intracranial hemorrhage or persistent/progressive focal neurological deficits in patients with CCM
The use of beta-blockers (rather than statins) reduces the risk of intracranial hemorrhage or persistent/progressive focal neurological deficits in patients with CCM
Original source:
Original source:Susanna M.